NUVB vs. CTMX

Last updated Apr 1, 2026

Compare and contrast key facts about Nuvation Bio Inc. (NUVB) and CytomX Therapeutics, Inc. (CTMX).

Performance

NUVB vs. CTMX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvation Bio Inc. (NUVB) and CytomX Therapeutics, Inc. (CTMX). The values are adjusted to include any dividend payments, if applicable.

NUVB vs. CTMX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NUVB Nuvation Bio Inc.	-52.12%	236.84%	76.16%	-21.35%	-77.41%	-27.35%	17.00%
CTMX CytomX Therapeutics, Inc.	10.33%	313.59%	-33.55%	-3.13%	-63.05%	-33.89%	-4.38%

Fundamentals

Market Cap NUVB : $1.48B CTMX : $799.88M
EPS NUVB : -$0.60 CTMX : -$0.11
PS Ratio NUVB : 23.36 CTMX : 9.55
PB Ratio NUVB : 4.83 CTMX : 8.08
Total Revenue (TTM) NUVB : $62.90M CTMX : $76.20M
Gross Profit (TTM) NUVB : $54.46M CTMX : $75.69M
EBITDA (TTM) NUVB : -$199.90M CTMX : -$19.39M

Returns By Period

In the year-to-date period, NUVB achieves a -52.12% return, which is significantly lower than CTMX's 10.33% return.

NUVB

• 1D: 5.93%
• 1M: -27.41%
• YTD: -52.12%
• 6M: 15.95%
• 1Y: 143.75%
• 3Y*: 37.23%
• 5Y*: -15.90%
• 10Y*: —

CTMX

• 1D: 6.58%
• 1M: -12.48%
• YTD: 10.33%
• 6M: 47.34%
• 1Y: 639.23%
• 3Y*: 46.01%
• 5Y*: -9.80%
• 10Y*: -9.91%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NUVB vs. CTMX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUVB

NUVB Risk / Return Rank: 83
NUVB Sharpe Ratio Rank: 85
NUVB Sortino Ratio Rank: 84
NUVB Omega Ratio Rank: 84
NUVB Calmar Ratio Rank: 81
NUVB Martin Ratio Rank: 80

CTMX

CTMX Risk / Return Rank: 98
CTMX Sharpe Ratio Rank: 98
CTMX Sortino Ratio Rank: 98
CTMX Omega Ratio Rank: 97
CTMX Calmar Ratio Rank: 99
CTMX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUVB vs. CTMX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and CytomX Therapeutics, Inc. (CTMX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NUVB	CTMX	Difference
Sharpe ratio Return per unit of total volatility	1.52	3.81	-2.29
Sortino ratio Return per unit of downside risk	2.35	4.71	-2.35
Omega ratio Gain probability vs. loss probability	1.32	1.61	-0.29
Calmar ratio Return relative to maximum drawdown	2.36	15.76	-13.40
Martin ratio Return relative to average drawdown	5.83	36.65	-30.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NUVB vs. CTMX - Sharpe Ratio Comparison

The current NUVB Sharpe Ratio is 1.52, which is lower than the CTMX Sharpe Ratio of 3.81. The chart below compares the historical Sharpe Ratios of NUVB and CTMX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NUVB	CTMX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.52	3.81	-2.29
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.21	-0.07	-0.14
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	-0.08	-0.11

Correlation

The correlation between NUVB and CTMX is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NUVB vs. CTMX - Dividend Comparison

Neither NUVB nor CTMX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NUVB vs. CTMX - Drawdown Comparison

The maximum NUVB drawdown since its inception was -93.39%, smaller than the maximum CTMX drawdown of -98.74%. Use the drawdown chart below to compare losses from any high point for NUVB and CTMX.

Drawdown Indicators

	NUVB	CTMX	Difference
Max Drawdown Largest peak-to-trough decline	-93.39%	-98.74%	+5.35%
Max Drawdown (1Y) Largest decline over 1 year	-57.55%	-41.14%	-16.41%
Max Drawdown (5Y) Largest decline over 5 years	-93.35%	-95.65%	+2.30%
Max Drawdown (10Y) Largest decline over 10 years	—	-98.74%	—
Current Drawdown Current decline from peak	-70.56%	-86.27%	+15.71%
Average Drawdown Average peak-to-trough decline	-65.43%	-70.40%	+4.97%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.29%	17.69%	+5.60%

Volatility

NUVB vs. CTMX - Volatility Comparison

The current volatility for Nuvation Bio Inc. (NUVB) is 33.02%, while CytomX Therapeutics, Inc. (CTMX) has a volatility of 53.47%. This indicates that NUVB experiences smaller price fluctuations and is considered to be less risky than CTMX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUVB	CTMX	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.02%	53.47%	-20.45%
Volatility (6M) Calculated over the trailing 6-month period	70.37%	74.27%	-3.90%
Volatility (1Y) Calculated over the trailing 1-year period	95.01%	169.33%	-74.32%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.97%	142.15%	-66.18%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	73.55%	111.35%	-37.80%

Financials